Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.59 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.58 |
| ▸ | NPY1R | P25929 | 1/20 | 0.58 |
| ▸ | NPY2R | P49146 | 1/20 | 0.58 |
| ▸ | NPY4R | P50391 | 1/20 | 0.58 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.58 |
| ▸ | CXCR4 | P61073 | 4/20 | 0.58 |
| ▸ | CXCL8 | P10145 | 4/20 | 0.57 |
| ▸ | GLP1R | P43220 | 6/20 | 0.56 |
| ▸ | GIPR | P48546 | 6/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30600981 | 0.98 | NPY1R (0.60) | TACR1KISS1RNPY1RNPY2RNPY4R | |
| SCHEMBL29949651 | 0.89 | NPY1R (0.67) | KISS1RNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL30414398 | 0.88 | NTSR2 (0.61) | TACR1KISS1RCXCR4CXCL8 | |
| SCHEMBL29418257 | 0.88 | BACE1 (0.62) | KISS1RGLP1RGIPR | |
| SCHEMBL31186286 | 0.88 | KISS1R (0.65) | TACR1KISS1RCXCR4CXCL8 | |
| SCHEMBL31182571 | 0.87 | NPY2R (0.71) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL29450205 | 0.87 | CXCL8 (0.62) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL30598998 | 0.87 | C5AR1 (0.58) | KISS1RNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL29533335 | 0.86 | TACR1 (0.62) | TACR1KISS1RCXCR4CXCL8 | |
| SCHEMBL28737909 | 0.86 | TACR1 (0.62) | TACR1KISS1RCXCR4CXCL8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025217401-A1 | A PEPTIDE INHIBITOR OF THE EYA AND PP2A-B55A INTERACTION USEFUL FOR MYC-DRIVEN CANCER THERAPY | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-10-16 | — | — | WO | claimed |
| EP-4077353-B1 | SYNTHESIS OF AMANIN AND ITS DERIVATIVES | HEIDELBERG PHARMA RES GMBH (DE) | 2025-04-23 | — | — | EP | claimed |
| US-20240173256-A1 | HDL MIMICKING TARGETED DRUG DELIVERY SYSTEM FOR THE TREATMENT OF SOLID TUMORS | UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER (US) | 2024-05-30 | — | — | US | claimed |
| CN-115666653-A | Antibody-drug conjugates | 斯皮雷亚有限公司 | 2023-01-31 | — | — | CN | claimed |
| CN-115472234-A | Hidden variable Gaussian process soft measurement modeling method integrating qualitative and quantitative information | 浙江工业大学 | 2022-12-13 | — | — | CN | claimed |
| CN-114599389-A | Variant FC domains and uses thereof | 奇达拉治疗公司 | 2022-06-07 | — | — | CN | claimed |
| US-20260062455-A1 | UPTAKE MECHANISM OF ESSENTIAL LYSOPHOSPHOLIPIDS INTO THE BRAIN AND INHIBITION BY ENDOGENOUS-RETROVIRAL ENVELOPE PROTEIN | PASTEUR INSTITUT (FR) | 2026-03-05 | — | — | US | disclosed |
| US-12467928-B2 | N-terminal modifier agents and binders for treating and analyzing peptides | DF PEPTIDE ACQUISITION LLC | 2025-11-11 | — | — | US | disclosed |
| US-12467049-B2 | Methods and kits using nucleic acid encoding and/or label | DF PEPTIDE ACQUISITION LLC | 2025-11-11 | — | — | US | disclosed |
| EP-4637797-A1 | METHOD FOR OBTAINING AN EXTRACT OF PLANT ORIGIN, A COMPOSITION CONTAINING IT AND ITS COSMETIC USE | SEDERMA (FR) | 2025-10-29 | — | — | EP | disclosed |
| US-20250295742-A1 | PHENYLALANINE-DEGRADING ENZYME VARIANTS AND TREATMENTS FOR PHENYLKETONURIA | IDITAROD BIO, INC. (US) | 2025-09-25 | — | — | US | disclosed |
| WO-2025128687-A1 | GLUCOSE-DEPENDENT DROPLETS AND SUPRAMOLECULAR PEPTIDE DEPOTS FOR GLUCOSE-RESPONSIVE GLUCAGON DELIVERY | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2025-06-19 | — | — | WO | disclosed |
| US-12319752-B2 | Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria | NORTHEASTERN UNIVERSITY (US) | 2025-06-03 | — | — | US | disclosed |
| CN-114302735-A | Peptide inhibitors of HIV capsid inhibition | 密苏里大学管理者 | 2022-04-08 | — | — | CN | disclosed |
| WO-2022072560-A1 | POLYPEPTIDE TERMINAL BINDERS AND USES THEREOF | Encodia, Inc. (US) | 2022-04-07 | — | — | WO | disclosed |
| EP-3966326-A1 | FMRP AND CANCER TREATMENT | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2022-03-16 | — | — | EP | disclosed |
| US-11274131-B2 | IgM-mediated receptor clustering and cell modulation | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-03-15 | — | — | US | disclosed |
| CN-114174338-A | Antibodies that bind to GPRC5D | 豪夫迈·罗氏有限公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-114174342-A | Antibodies that bind to GPRC5D | 豪夫迈·罗氏有限公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-114127123-A | Fusion of CEA-binding antibodies to 4-1BBL | 豪夫迈·罗氏有限公司 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12319752-B2 | Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria | NGLY1, HM13, VIP | TACR1 1973/4885KISS1R 2271/4885NPY1R 3148/4885 |
| US-20260062455-A1 | UPTAKE MECHANISM OF ESSENTIAL LYSOPHOSPHOLIPIDS INTO THE BRAIN AND INHIBITION BY ENDOGENOUS-RETROVIRAL ENVELOPE PROTEIN | SNAP29, SLC18A2, NSF | TACR1 3397/4885KISS1R 1209/4885NPY1R 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.